Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Theo Dingermann

Showing results (71-80 of 85) with videos related to

Pageof 9
Sort By:
Pharmazie in Unserer Zeit|August 30, 2008
[New therapeutic approaches in cystic fibrosis]Anne Vestner, Barbara Schrepfer, Jutta Kockler, et al.
Pharmazie in Unserer Zeit|July 12, 2007
[No entry]Anita Schuwald, Thomas Taupitz, Katharina Köper, et al.
European Journal of Haematology|June 30, 2009
Two independent gene signatures in pediatric t(4;11) acute lymphoblastic leukemia patientsLuca Trentin, Marco Giordan, Theo Dingermann, et al.
Biochemical Pharmacology|November 26, 2002
Hyperforin is a dual inhibitor of cyclooxygenase-1 and 5-lipoxygenaseDana Albert, Ilse Zündorf, Theo Dingermann, et al.
Blood|March 3, 2010
The AF4.MLL fusion protein is capable of inducing ALL in mice without requirement of MLL.AF4Adelheid Bursen, Karen Schwabe, Brigitte Rüster, et al.
Pharmazie in Unserer Zeit|February 14, 2014
[Not Available]Alissa Linder, Giorgio Marino, Julia Prechtel, et al.
Biotechnology Journal|August 8, 2006
Genomic DNA of leukemic patients: target for clinical diagnosis of MLL rearrangementsClaus Meyer, Eric Kowarz, Björn Schneider, et al.
Biochemical and Biophysical Research Communications|May 22, 2007
Extracellular signal-regulated kinase-2 phosphorylates RORalpha4 in vitroAdriane Lechtken, Michael Hörnig, Oliver Werz, et al.
Journal of Medicinal Chemistry|February 21, 2003
Structure-activity relationships of dimethindene derivatives as new M2-selective muscarinic receptor antagonistsThomas M Böhme, Christine Keim, Kai Kreutzmann, et al.
Pharmazie in Unserer Zeit|July 3, 2009
[Clinically relevant interaction between clopidogrel and proton pump inhibitors]Susanne Alban, Theo Dingermann, Nina Griese, et al.
Pageof 9

Showing results (71-80 of 85) with videos related to

Sort By:
Pageof 9
Pharmazie in Unserer Zeit|August 30, 2008
[New therapeutic approaches in cystic fibrosis]Anne Vestner, Barbara Schrepfer, Jutta Kockler, et al.
Pharmazie in Unserer Zeit|July 12, 2007
[No entry]Anita Schuwald, Thomas Taupitz, Katharina Köper, et al.
European Journal of Haematology|June 30, 2009
Two independent gene signatures in pediatric t(4;11) acute lymphoblastic leukemia patientsLuca Trentin, Marco Giordan, Theo Dingermann, et al.
Biochemical Pharmacology|November 26, 2002
Hyperforin is a dual inhibitor of cyclooxygenase-1 and 5-lipoxygenaseDana Albert, Ilse Zündorf, Theo Dingermann, et al.
Blood|March 3, 2010
The AF4.MLL fusion protein is capable of inducing ALL in mice without requirement of MLL.AF4Adelheid Bursen, Karen Schwabe, Brigitte Rüster, et al.
Pharmazie in Unserer Zeit|February 14, 2014
[Not Available]Alissa Linder, Giorgio Marino, Julia Prechtel, et al.
Biotechnology Journal|August 8, 2006
Genomic DNA of leukemic patients: target for clinical diagnosis of MLL rearrangementsClaus Meyer, Eric Kowarz, Björn Schneider, et al.
Biochemical and Biophysical Research Communications|May 22, 2007
Extracellular signal-regulated kinase-2 phosphorylates RORalpha4 in vitroAdriane Lechtken, Michael Hörnig, Oliver Werz, et al.
Journal of Medicinal Chemistry|February 21, 2003
Structure-activity relationships of dimethindene derivatives as new M2-selective muscarinic receptor antagonistsThomas M Böhme, Christine Keim, Kai Kreutzmann, et al.
Pharmazie in Unserer Zeit|July 3, 2009
[Clinically relevant interaction between clopidogrel and proton pump inhibitors]Susanne Alban, Theo Dingermann, Nina Griese, et al.
Pageof 9